Mirum Reconciled Depreciation from 2010 to 2025

MIRM Stock  USD 45.99  0.29  0.63%   
Mirum Pharmaceuticals Reconciled Depreciation yearly trend continues to be very stable with very little volatility. Reconciled Depreciation is likely to grow to about 24.8 M this year. During the period from 2010 to 2025, Mirum Pharmaceuticals Reconciled Depreciation quarterly data regression pattern had sample variance of 65.5 T and median of  324,000. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2019-03-31
Previous Quarter
6.1 M
Current Value
6.1 M
Quarterly Volatility
2.3 M
 
Covid
Check Mirum Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mirum Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 14.5 M, Discontinued Operations of 0.0 or Interest Expense of 10.3 M, as well as many indicators such as Price To Sales Ratio of 5.54, Dividend Yield of 0.0 or PTB Ratio of 9.14. Mirum financial statements analysis is a perfect complement when working with Mirum Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Mirum Pharmaceuticals Correlation against competitors.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.

Latest Mirum Pharmaceuticals' Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of Mirum Pharmaceuticals over the last few years. It is Mirum Pharmaceuticals' Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mirum Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

Mirum Reconciled Depreciation Regression Statistics

Arithmetic Mean3,996,091
Geometric Mean874,327
Coefficient Of Variation202.58
Mean Deviation5,428,772
Median324,000
Standard Deviation8,095,402
Sample Variance65.5T
Range24.5M
R-Value0.67
Mean Square Error38.3T
R-Squared0.45
Significance0
Slope1,146,664
Total Sum of Squares983T

Mirum Reconciled Depreciation History

202524.8 M
202423.6 M
2023M
20223.7 M
2021975 K
2020623 K

About Mirum Pharmaceuticals Financial Statements

Mirum Pharmaceuticals investors utilize fundamental indicators, such as Reconciled Depreciation, to predict how Mirum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Reconciled Depreciation23.6 M24.8 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Mirum Pharmaceuticals is a strong investment it is important to analyze Mirum Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mirum Pharmaceuticals' future performance. For an informed investment choice regarding Mirum Stock, refer to the following important reports:
Check out the analysis of Mirum Pharmaceuticals Correlation against competitors.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.84)
Revenue Per Share
7.089
Quarterly Revenue Growth
0.429
Return On Assets
(0.08)
Return On Equity
(0.37)
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.